The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: C. M. Dintsios, I. Beinhauer
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-03-01
Col·lecció:Health Economics Review
Matèries:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Accés en línia:http://link.springer.com/article/10.1186/s13561-020-00263-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars